Hepatitis C Management in Special Populations
Summary
- The AASLD/IDSA guidelines recommend that all children with chronic HCV infection who are 3 years of age or older should receive treatment with an approved DAA regimen, regardless of disease severity[AASLD-IDSA HCV]
- Glecaprevir/pibrentasvir is the first choice for adolescent treatment of HCV and is approved for adolescents aged 12-17 years with any HCV genotype
- Ledipasvir/sofosbuvir and sofosbuvir plus ribavirin are approved by the FDA for the treatment of HCV infection in patients 3 years of age and older
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content